Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Medicus Pharma Ltd.

NASDAQ: MDCX · Life Sciences · 7 alerts · CIK 1997296

Share price
$1.69Close, Nov 16
Market cap
$3.25M
Shares outstanding
1.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Medicus Pharma Ltd. filings on SEC EDGAR ↗

7:31 AM ET 8-K
Capital Raise

Medicus Pharma Capital Raise of $3M

Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.

Value
$3M
4:07 PM ET 10-Q
Financial Results

Medicus Pharma Q3 2026 Results: Net Loss of $15.2M, Loss Narrows

Medicus Pharma Ltd. reported a net loss of $35.9 million for the nine months ended September 30, 2026, driven by $10 million in IPR&D charges and increased R&D spending. The company significantly strengthened its cash position through $17.2 million in ATM proceeds and $22 million from debentures, though it maintains a total shareholders' deficit of $10.5 million.

Key figure
Net loss $15.2M
5:31 PM ET 8-K
M&A Deal

Medicus Pharma Announces $135M M&A Deal

Medicus Pharma announced that its wholly-owned subsidiary, SkinJect, Inc., has entered into a non-binding letter of intent for a business combination with an undisclosed SPAC. The proposed transaction contemplates a $135 million pre-money enterprise valuation for SkinJect and is expected to close in the first half of 2027, with Medicus seeking to retain majority ownership.

Value
$135M

“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders. The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”

Dr. Raza Bokhari, Medicus Exec. Chairman and CEO
5:15 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Medicus Pharma Nasdaq/NYSE Compliance Notice

Medicus Pharma Ltd. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for ten consecutive business days. This compliance notice supersedes a delisting determination letter received on October 20, 2026, which had initially triggered a delisting process due to the company's failure to meet the bid price and stockholders' equity requirements.

Counterparty
Nasdaq

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.